TS1622349808	drug 150 175	tyrosine kinase inhibitor
TS922349808	treatedDisease 367 387	early Phase 1 cancer
TS122349808	treatedDisease 628 634	cancer
TS1222349808	mealTime 937 952	A high-fat meal
TS2222349808	mealTime 1046 1052	Fasted
TS722349808	drug 1272 1275	AUC
TS1422349808	sideeffect 1675 1681	cancer
TS2022349808	drug2 1771 1777	lipid-
T1	drug 48 58	amuvatinib
T2	drug 119 129	Amuvatinib
T3	drug 292 302	Amuvatinib
R3	treat Arg1:T3 Arg2:TS922349808	
T4	modeadm 308 335	dry-powder capsules ( DPC )
T5	numbers 689 691	58
T6	drug 742 752	amuvatinib
T7	modeadm 753 756	DPC
T8	drug 805 815	amuvatinib
T9	modeadm 816 819	DPC
T10	sideeffect 718 729	food-effect
T11	modeadm 829 869	lipid- lipid-suspension capsules ( LSC )
T12	drug 920 930	amuvatinib
T13	modeadm 931 934	LSC
T14	drug 971 981	amuvatinib
T15	modeadm 982 985	DPC
T16	food 937 947	A high-fat
R1	increase_absorption Arg1:T16 Arg2:T14	
T17	drug 1126 1136	amuvatinib
T18	drug 1190 1200	amuvatinib
T19	modeadm 1201 1204	LSC
T20	drug 1290 1300	amuvatinib
T21	modeadm 1301 1304	DPC
T22	drug 1349 1359	amuvatinib
T23	modeadm 1360 1363	LSC
T24	dosage 1364 1370	300 mg
T25	frequency 1384 1393	every 8 h
T26	sideeffect 1601 1614	adverse event
T27	drug 1617 1627	Amuvatinib
T28	modeadm 1628 1631	LSC
T29	dosage 1634 1640	300 mg
T30	frequency 1641 1650	every 8 h
T31	drug 1750 1760	amuvatinib
T32	modeadm 1761 1764	DPC
T33	modeadm 1776 1799	lipid-based formulation
